SPONSORED: Do Your Patients Have Sporadic COPD Flare-Ups?
If you have patients with COPD that has been difficult to manage, they may be eligible to participate in a clinical study called RESOLUTE. Flare-ups — when COPD symptoms are much worse than usual — can impact quality of life and overall health and wellness for patients with COPD. The RESOLUTE clinical study is evaluating whether a newer kind of more targeted investigational medicine brings any benefit when used in combination with the inhaler medications patients with COPD are already using. Patients may be eligible to join the study if they:
- Are aged 40–85 years;
- Have been diagnosed with advanced COPD based on a spirometry test;
- Have experienced 3 or more flare-ups in the past year that required medical treatment;
- Are a current or ex-smoker who has smoked 20 cigarettes a day for at least 1 year;
- Have used triple combination inhaler therapy, which includes inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA) for the previous 3 months or more; and
- Have used at least double inhaled therapy of ICS and either LABA or LAMA for the previous year.
For more information call 1-877-240-9479 or write to [email protected]. Patients can also find out more by visiting ClinicalTrials.gov and using the trial identifier NCT04053634.
